Economic Issues: Toward a Cost-Effective Approach to the Management of Febrile Neutropenia in Japan

Masaoka, Tohru
July 2004
Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS68
Academic Journal
The cost of treating neutropenic patients unexplained fever is of significant concern in Japan because of the depressed economy and the aging population. Development of a standardized treatment methodology specifically tailored to the situation in Japan will make the treatment more efficient for health care institutions, will allow for improved monitoring of practices and costs, and will result in better patient care. It is essential, however, that the welfare of the patients be the utmost priority—cost savings is not sufficient in the absence of a significant impact on morbidity and mortality.


Related Articles

  • Febrile neutropenia costly in the US.  // PharmacoEconomics & Outcomes News;9/1/2012, Issue 661, p8 

    The article discusses research on the costs associated with febrile neutropenia in the U.S., referencing a study by S. I. Michels and colleagues published in a 2012 issue of "PharmacoEconomics."

  • Outpatient treatment of febrile neutropenia is viable.  // PharmacoEconomics & Outcomes News;2/23/2008, Issue 547, p5 

    The article discusses research being done on outcomes and cost of outpatient or inpatient management of patients with febrile neutropenia. It references a study by L. S. Elting, published in the February 1, 2008 issue of the "Journal of Clinical Oncology." Researchers contend that outpatient...

  • Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia. Bucaneve, G.; Menichetti, F.; Favero, A.D.; Del Favero, A // PharmacoEconomics;1999, Vol. 15 Issue 1, p85 

    Objective: Patients with cancer-associated neutropenia are at high risk of developing severe infections which can be fatal if treatment is not promptly administered. For this reason, fever is treated as soon as possible with broad spectrum antibacterial therapy. The objective of...

  • Chemo-induced neutropenia: impact under-appreciated.  // Reactions Weekly;6/13/2009, Issue 1256, p4 

    The article discusses research on costs and outcomes associated with hospitalizations for chemotherapy-induced neutropenia. It references two studies presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in May 2009. The first study analysed the contribution of...

  • Costs Associated with Febrile Neutropenia in the US. Michels, Shannon L.; Barron, Rich L.; Reynolds, Matthew W.; Tomic, Karen Smoyer; Yu, Jingbo; Lyman, Gary H. // PharmacoEconomics;2012, Vol. 30 Issue 9, p809 

    Background and Objective: Febrile neutropenia (FN) is a potentially lifethreatening condition that may develop in cancer patients treated with myelosuppressive chemotherapy and result in considerable costs. This study was designed to estimate US healthcare utilization and costs in those...

  • Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department Care. Courtney, D. Mark; Aldeen, Amer Z.; Gorman, Stephen M.; Handler, Jonathan A.; Trifilio, Steven M.; Parada, Jorge P.; Yarnold, Paul R.; Bennett, Charles L. // Oncologist;Aug2007, Vol. 12 Issue 8, p1019 

    Purpose. Febrile neutropenia (FN) is a common, costly, and potentially fatal complication in oncology. While FN in the inpatient setting has been extensively studied, only one study has evaluated emergency department (ED) care for FN cancer patients. That study found that 96% of patients...

  • Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice. Weycker, Derek; Danel, Aurelie; Marciniak, Anne; Bendall, Kate; Lipsitz, Michael; Pettengell, Ruth // BMC Cancer;2012, Vol. 12 Issue 1, p362 

    Background: Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown. Methods: Data were obtained from a European (97%) and Australian (3%) observational study of patients with non-Hodgkin’s lymphoma (NHL)...

  • Cost Comparison of Antibacterial Therapies for Serious Infections: A New Zealand 3-Hospital Study. Hicks, P.; Scott, W.G.; Cotterell, P.; Scott, H.M.; Henderson, S.; Inder, A.; Sanders, J.; Spearing, R.; McArthur, C.; Judson, J.; Baker, B. // PharmacoEconomics;1999, Vol. 16 Issue 2, p183 

    Objective: The first aim was to identify and determine the economic costs of the regimens currently used in 3 New Zealand hospitals in the treatment of bacterial infections in haematology patients with febrile neutropenia and in intensive care patients with severe infections. The second was to...

  • Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. Trueman, P. // British Journal of Cancer;9/15/2009 Supplement 1, Vol. 101, pS15 

    Although the use of prophylactic granulocyte colony-stimulating factor (G-CSF) in conjunction with myelosuppressive chemotherapy is supported by clinical research evidence and advocated by international clinical guidelines when the consequent risk of febrile neutropenia exceeds 20%, there...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics